These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 8996853

  • 21. A novel approach to the specification of in-vitro dissolution boundaries based on regulatory requirements for bioequivalence.
    Steinijans VW, Dietrich R, Trautmann H, Sauter R, Benedikt G.
    Arzneimittelforschung; 1988 Aug; 38(8A):1238-40. PubMed ID: 3190812
    [Abstract] [Full Text] [Related]

  • 22. Single dose study of the bioequivalence of two sustained-release theophylline formulations.
    Contreras J, Pérez N, González R, Ontivero E, López M.
    Arzneimittelforschung; 1998 Mar; 48(3):259-62. PubMed ID: 9553683
    [Abstract] [Full Text] [Related]

  • 23. Steady-state pharmacokinetics of a once-daily theophylline formulation (Euphylong) when given twice daily.
    Götz J, Sauter R, Steinijans VW, Jonkman JH.
    Int J Clin Pharmacol Ther; 1994 Apr; 32(4):168-73. PubMed ID: 8032575
    [Abstract] [Full Text] [Related]

  • 24. Theophylline controlled-release formulations: in vivo-in vitro correlations.
    Yu Z, Schwartz JB, Sugita ET.
    Biopharm Drug Dispos; 1996 Apr; 17(3):259-72. PubMed ID: 8983400
    [Abstract] [Full Text] [Related]

  • 25. [Comparative study of sustained-release in theophylline (Slobid, Theolong, Theodur) by pharmacokinetics].
    Kotake T, Mihara M, Shibakawa M, Asamoto.
    Arerugi; 1997 Apr; 46(4):370-5. PubMed ID: 9154697
    [Abstract] [Full Text] [Related]

  • 26. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O, Alvarez JC.
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [Abstract] [Full Text] [Related]

  • 27. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
    Hayashi T, Kanbe H, Okada M, Kawase I, Ikeda Y, Onuki Y, Kaneko T, Sonobe T.
    Int J Pharm; 2007 Aug 16; 341(1-2):105-13. PubMed ID: 17512147
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA, Villalpando-Hernández J, Novoa-Heckel G, Oliva I, Cariño L, López-Bojórquez E, Burke-Fraga V, Namur S, González-de la Parra M.
    Clin Ther; 2009 Feb 16; 31(2):399-410. PubMed ID: 19302912
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA, Tamimi JJ, Salem II, Ibrahim H, Sallam AA.
    Clin Ther; 2008 Oct 16; 30(10):1831-43. PubMed ID: 19014838
    [Abstract] [Full Text] [Related]

  • 33. Effect of gallbladder contraction induced cholagogia on the pharmacokinetic profile of a sustained-release theophylline formulation.
    Fuchs WS, von Nieciecki A, Molz KH, Popescu G, Weil A, Barkworth MF, Gay S, Laicher A, Stanislaus F.
    Arzneimittelforschung; 1996 Dec 16; 46(12):1120-6. PubMed ID: 9006785
    [Abstract] [Full Text] [Related]

  • 34. Comparative dose study of a theophylline sustained-release tablet formulation after repeated administrations.
    Cova D, Cuglituri G, Rossini L, Bonfardeci G.
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun 16; 27(6):273-5. PubMed ID: 2737795
    [Abstract] [Full Text] [Related]

  • 35. Influence of gastric pH changes on pharmacokinetic of a sustained-release formulation of theophylline.
    Ferrari M, Olivieri M, Romito D, Biasin C, Barozzi E, Bassetti S.
    Riv Eur Sci Med Farmacol; 1991 Jun 16; 13(5-6):269-74. PubMed ID: 1819857
    [Abstract] [Full Text] [Related]

  • 36. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y, Lee L, Somma R, Thompson G, Bakhtiar R, Lee J, Rekhi GS, Lau H, Sedek G, Hossain M.
    Biopharm Drug Dispos; 2004 Mar 16; 25(2):91-8. PubMed ID: 14872557
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics of an extended-release theophylline product in cats.
    Guenther-Yenke CL, McKiernan BC, Papich MG, Powell E.
    J Am Vet Med Assoc; 2007 Sep 15; 231(6):900-6. PubMed ID: 17867974
    [Abstract] [Full Text] [Related]

  • 38. Comparative absorption of theophylline following multiple doses of a sustained-release formulation and an elixir in humans.
    Harrison LI, French IW, Mildon CA.
    Clin Ther; 1982 Sep 15; 4(6):489-96. PubMed ID: 7093982
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Absorption profile and absolute bioavailability of a theophylline sustained-release preparation].
    Pabst G, Weber W, Barkworth MF, Müller M, Rehm KD.
    Arzneimittelforschung; 1998 May 15; 48(5A):574-9. PubMed ID: 9676347
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.